Pharmaceutics Division, Central Drug Research Institute, CSIR, Lucknow 226001, India.
Tuberculosis (Edinb). 2011 Jan;91(1):65-6. doi: 10.1016/j.tube.2010.10.001. Epub 2010 Nov 23.
Factors that are inimical to the success of inhaled therapies for tuberculosis (TB) include: (i) lack of access of inhaled therapies to poorly-aerated areas of the tubercular lung; (ii) limited ability to penetrate biofilms formed by extracellular bacilli; (iii) selection for resistant bacilli on account of administration of low doses of anti-TB agents; (iv) induction of inflammation and/or immunopathology in the airways and lungs; and (v) anomalies in antigen processing and presentation of vaccines delivered to the lungs. Further, the claim that inhaled therapies rescue alternatively-activated macrophages may not be applicable to all individuals. Fortunately, there are ways and means to address each of the above factors.
对结核病(TB)吸入治疗成功不利的因素包括:(i)吸入疗法无法到达结核肺部通气不良的区域;(ii)穿透由胞外杆菌形成的生物膜的能力有限;(iii)由于给予低剂量抗结核药物,选择耐药杆菌;(iv)在气道和肺部引起炎症和/或免疫病理;以及(v)递送到肺部的疫苗的抗原加工和呈递异常。此外,吸入治疗拯救交替激活的巨噬细胞的说法可能不适用于所有人。幸运的是,有方法可以解决上述每个因素。